Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q3 2017 · 10-Q
Revenue$249.80K$249.80K−77.0% vs Q3 2016 Net Income-$111.56K-$111.56KN/M vs Q3 2016 EPS Diluted$0.00$0.00N/M vs Q3 2016 Operating Income-$386,112N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$69,399N/M Margins · derivedOperating margin-154.6%−120.0 pt vs Q3 2016
Net margin-44.7%−7.5 pt vs Q3 2016
ended Dec 31, 2016 · filed Feb 21, 2017 · 52 d after period end